drugset

drugset / Trial / NCT05419869

Pilot Decentralized Trial

NCT05419869 ↗

Phase 2 Completed 21 enrolled Alto Neuroscience

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-100.

Timeline

Start: 2022-06-01
Primary completion: 2023-01-13
Completion: 2023-01-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALTO-100	Unknown	—	Oral

Indications